Sirona Biochem（SRBC.F）株式概要化粧品原料および創薬企業のシロナ・バイオケム社は、カナダとフランスで化粧品および医薬品の有効成分を開発・販売している。 詳細SRBC.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析最新の財務報告は1年以上前のものである 意味のある時価総額がありません ( $265 )株式の流動性は非常に低い すべてのリスクチェックを見るSRBC.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.000001該当なし内在価値ディスカウントEst. Revenue$PastFuture-5m1m2016201920222025202620282031Revenue CA$1.0Earnings CA$0.2AdvancedSet Fair ValueView all narrativesSirona Biochem Corp. 競合他社AditxtSymbol: NasdaqCM:ADTXMarket cap: US$57.2kVincerx PharmaSymbol: OTCPK:VINCMarket cap: US$89.0kSynairgenSymbol: OTCPK:SYGG.FMarket cap: US$110.3kLipella PharmaceuticalsSymbol: OTCPK:LIPOMarket cap: US$166.4k価格と性能株価の高値、安値、推移の概要Sirona Biochem過去の株価現在の株価US$0.00000152週高値US$0.02152週安値US$0.000001ベータ01ヶ月の変化n/a3ヶ月変化n/a1年変化-99.90%3年間の変化-99.90%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • Apr 23Sirona Biochem Corp. announced that it expects to receive CAD 0.4 million in fundingSirona Biochem Corp. announced a non-brokered private placement that it will issue up to 400 unsecured convertible debentures units at an issue price of CAD 1,000 per unit for the gross proceeds of up to CAD 400,000 on April 22, 2025. Each Debenture Unit will have a face value of of CAD 1,120, consisting of CAD 1,000 in principal and CAD 120 in prepaid interest. The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, and such accrued interest will be paid semi-annually, in arrears. At the election of the Company, Prepaid Interest and Accrued Interest may be paid in cash or converted into Shares at a conversion price equal to the maximum Discounted Market Price equal to the maximum Discounted Market Price. The holder may, at its option, convert in full or in part, the Principal at any time prior to the maturity date, being the third anniversary of the issue date, into units of the Company at CAD 0.10 per Unit. Upon conversion of the Principal, Prepaid Interest and unpaid Accrued Interest, will be, at the election of the Company, either paid in cash or converted into Shares at the Interest Conversion Price. Each Unit will consist of one Share and one non-transferable share purchase warrant. Each Unit will consist of one Share and one non-transferable share purchase warrant at an exercise price of CAD 0.15 at any time prior to the Maturity Date. The Company shall have the right to redeem the Convertible Debentures prior to the Maturity Date at any time after 6 months from the issue date, by paying holders in cash the Face Value of the Convertible Debentures, together with all Prepaid and Accrued Interest and a redemption penalty payment of 8% of the Face Value. The closing of the Offering is subject to the receipt of necessary regulatory approvals, including the approval of the TSXV. The Convertible Debentures, Shares, Warrants and any Warrant Shares will be subject to a four month hold period under applicable securities laws and TSXV policies. The Company may pay eligible finders a fee in connection with the Offering.お知らせ • Apr 22Sirona Biochem Corp. announced that it expects to receive CAD 3 million in funding from Promura GmbHSirona Biochem Corp. announced that it has entered into a investment agreement with Promura GmbH to issue unsecured convertible debentures for gross proceeds of CAD 3,000,000 on April 22, 2025. The debentures will accrue interest at the rate of 12%. The company plans to compensate finders by way of cash fees and warrants. The completion of the private placement is subject to customary conditions, including acceptance from the Toronto stock exchange venture. All securities issued will be subject to a hold period in accordance with TSXV and/or other regulatory requirements.お知らせ • Apr 05Sirona Biochem Corp. announced that it has received CAD 0.1325 million in fundingOn April 4, 2024, Sirona Biochem Corp closed the transaction. The company has now issued 1,325,000 units at a price of CAD 0.10 per Unit for a gross proceeds of CAD 132,500. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024. No insiders participated in the private placement. No finders' fees were paid from the private placement.お知らせ • Feb 02Sirona Biochem Corp. announced that it expects to receive CAD 1 million in fundingSirona Biochem Corp. announced that it has entered into a private placement of promissory note for aggregate principal amount of $1,000,000 on January 29, 2024. The transaction will include participation from new lender, 0906462 B.C. Ltd. The promissory note will interest at a rate of 12% per annum. The Company has agreed to, subject to TSX Venture Exchange approval.お知らせ • Jan 27Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024.お知らせ • Dec 12Sirona Biochem Corp. Initiates GlycoProteMim™? Trademark for Anti-Aging Molecule TFC-1326Sirona Biochem Corp. announced the trademarking of its anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim. This pivotal decision marks a significant milestone in Sirona Biochem's mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim, filed with the Instituto Nacional da Propriedade Industrial (INPI) and the United States Trademark and Patent Office, demonstrates the company's unwavering commitment to revolutionizing the cosmetics industry with cutting-edge science and unparalleled anti-aging solutions. With over two decades of research and development, Sirona Biochem has developed GlycoProteMim (TFC-1326) into a powerful solution to reverse skin aging. The molecule has proven to be a game-changer in the fight against aging, offering a diverse range of permanent benefits. Sirona Biochem has begun the trademarking process through it's subsidiary TFChem and is actively engaging industry experts to chart the most effective course for commercializing GlycoProteMim™. This strategic move underscores the company's dedication to delivering a unique and transformative anti-aging solution to the $12.5 billion global anti-aging market. The choice to trademark GlycoProteMim goes beyond a mere formality; it stands as a testament to Sirona Biochem's commitment to revolutionizing beauty through scientific innovation. Through rigorous research and clinical trials, the company firmly believes that this name will soon be associated with timeless, radiant skin. Sirona Biochem is certain that GlycoProteMim will surpass the current gold standard, Retinol, in its ability to reverse skin aging. Unlike other products on the market, GlycoProteMim provides powerful results with exceptional tolerability.最新情報をもっと見るRecent updatesお知らせ • Apr 23Sirona Biochem Corp. announced that it expects to receive CAD 0.4 million in fundingSirona Biochem Corp. announced a non-brokered private placement that it will issue up to 400 unsecured convertible debentures units at an issue price of CAD 1,000 per unit for the gross proceeds of up to CAD 400,000 on April 22, 2025. Each Debenture Unit will have a face value of of CAD 1,120, consisting of CAD 1,000 in principal and CAD 120 in prepaid interest. The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, and such accrued interest will be paid semi-annually, in arrears. At the election of the Company, Prepaid Interest and Accrued Interest may be paid in cash or converted into Shares at a conversion price equal to the maximum Discounted Market Price equal to the maximum Discounted Market Price. The holder may, at its option, convert in full or in part, the Principal at any time prior to the maturity date, being the third anniversary of the issue date, into units of the Company at CAD 0.10 per Unit. Upon conversion of the Principal, Prepaid Interest and unpaid Accrued Interest, will be, at the election of the Company, either paid in cash or converted into Shares at the Interest Conversion Price. Each Unit will consist of one Share and one non-transferable share purchase warrant. Each Unit will consist of one Share and one non-transferable share purchase warrant at an exercise price of CAD 0.15 at any time prior to the Maturity Date. The Company shall have the right to redeem the Convertible Debentures prior to the Maturity Date at any time after 6 months from the issue date, by paying holders in cash the Face Value of the Convertible Debentures, together with all Prepaid and Accrued Interest and a redemption penalty payment of 8% of the Face Value. The closing of the Offering is subject to the receipt of necessary regulatory approvals, including the approval of the TSXV. The Convertible Debentures, Shares, Warrants and any Warrant Shares will be subject to a four month hold period under applicable securities laws and TSXV policies. The Company may pay eligible finders a fee in connection with the Offering.お知らせ • Apr 22Sirona Biochem Corp. announced that it expects to receive CAD 3 million in funding from Promura GmbHSirona Biochem Corp. announced that it has entered into a investment agreement with Promura GmbH to issue unsecured convertible debentures for gross proceeds of CAD 3,000,000 on April 22, 2025. The debentures will accrue interest at the rate of 12%. The company plans to compensate finders by way of cash fees and warrants. The completion of the private placement is subject to customary conditions, including acceptance from the Toronto stock exchange venture. All securities issued will be subject to a hold period in accordance with TSXV and/or other regulatory requirements.お知らせ • Apr 05Sirona Biochem Corp. announced that it has received CAD 0.1325 million in fundingOn April 4, 2024, Sirona Biochem Corp closed the transaction. The company has now issued 1,325,000 units at a price of CAD 0.10 per Unit for a gross proceeds of CAD 132,500. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024. No insiders participated in the private placement. No finders' fees were paid from the private placement.お知らせ • Feb 02Sirona Biochem Corp. announced that it expects to receive CAD 1 million in fundingSirona Biochem Corp. announced that it has entered into a private placement of promissory note for aggregate principal amount of $1,000,000 on January 29, 2024. The transaction will include participation from new lender, 0906462 B.C. Ltd. The promissory note will interest at a rate of 12% per annum. The Company has agreed to, subject to TSX Venture Exchange approval.お知らせ • Jan 27Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024.お知らせ • Dec 12Sirona Biochem Corp. Initiates GlycoProteMim™? Trademark for Anti-Aging Molecule TFC-1326Sirona Biochem Corp. announced the trademarking of its anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim. This pivotal decision marks a significant milestone in Sirona Biochem's mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim, filed with the Instituto Nacional da Propriedade Industrial (INPI) and the United States Trademark and Patent Office, demonstrates the company's unwavering commitment to revolutionizing the cosmetics industry with cutting-edge science and unparalleled anti-aging solutions. With over two decades of research and development, Sirona Biochem has developed GlycoProteMim (TFC-1326) into a powerful solution to reverse skin aging. The molecule has proven to be a game-changer in the fight against aging, offering a diverse range of permanent benefits. Sirona Biochem has begun the trademarking process through it's subsidiary TFChem and is actively engaging industry experts to chart the most effective course for commercializing GlycoProteMim™. This strategic move underscores the company's dedication to delivering a unique and transformative anti-aging solution to the $12.5 billion global anti-aging market. The choice to trademark GlycoProteMim goes beyond a mere formality; it stands as a testament to Sirona Biochem's commitment to revolutionizing beauty through scientific innovation. Through rigorous research and clinical trials, the company firmly believes that this name will soon be associated with timeless, radiant skin. Sirona Biochem is certain that GlycoProteMim will surpass the current gold standard, Retinol, in its ability to reverse skin aging. Unlike other products on the market, GlycoProteMim provides powerful results with exceptional tolerability.お知らせ • Jun 29Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing At the ICGEBSirona Biochem Corp. announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology (ICGEB). The compounds, generated by Sirona's subsidiary TFChem, are aimed at expanding Sirona's existing library of antiviral drug candidates. The ICGEB, located in Trieste, Italy, will employ specialized assays developed at their Laboratory of Molecular Virology to screen a library of 18 newly produced candidates, for their potential to inhibit SARS-CoV2. Spearheading the research program is Dr. Alessandro Marcello, a globally recognized authority in Human Virology. Building upon the previous screening results of the initial 20 compounds, these newly selected candidates hold significant promise. Testing is slated to commence within the next month. Sirona Biochem remains committed to advancing the program on antiviral research and remains optimistic about the potential impact these new compound candidates may have in combatting viral diseases.株主還元SRBC.FUS BiotechsUS 市場7D0%-1.6%-0.3%1Y-99.9%34.3%24.0%株主還元を見る業界別リターン: SRBC.F過去 1 年間で34.3 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: SRBC.Fは、過去 1 年間で24 % のリターンを上げたUS市場を下回りました。価格変動Is SRBC.F's price volatile compared to industry and market?SRBC.F volatilitySRBC.F Average Weekly Movementn/aBiotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.1%安定した株価: SRBC.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のSRBC.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2006n/aHoward Verricowww.sironabiochem.comシロナ・バイオケム社は化粧品原料および創薬会社で、カナダとフランスで化粧品および医薬品の有効成分を開発・販売している。同社のプログラムには、化粧品用美白剤と糖尿病治療薬が含まれ、その他のプロジェクトには、抗老化/細胞保護ライブラリ、新規抗シワ化合物、抗ウイルスプログラムの開発が含まれる。同社は以前はHigh Rider Capital Inc.として知られ、2009年5月にSirona Biochem Corp.に社名を変更した。Sirona Biochem Corp.は2006年に設立され、カナダのバンクーバーに本社を置いています。もっと見るSirona Biochem Corp. 基礎のまとめSirona Biochem の収益と売上を時価総額と比較するとどうか。SRBC.F 基礎統計学時価総額US$265.00収益（TTM）-US$1.94m売上高(TTM)n/a0.0xP/Sレシオ0.0xPER（株価収益率SRBC.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SRBC.F 損益計算書（TTM）収益-CA$16.36k売上原価CA$65.13k売上総利益-CA$81.49kその他の費用CA$2.58m収益-CA$2.67m直近の収益報告Jul 31, 2024次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%SRBC.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/18 01:02終値2026/05/07 00:00収益2024/07/31年間収益2023/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sirona Biochem Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Ellis AcklinFirst Berlin Equity Research GmbHJens HasselmeierFirst Berlin Equity Research GmbH
お知らせ • Apr 23Sirona Biochem Corp. announced that it expects to receive CAD 0.4 million in fundingSirona Biochem Corp. announced a non-brokered private placement that it will issue up to 400 unsecured convertible debentures units at an issue price of CAD 1,000 per unit for the gross proceeds of up to CAD 400,000 on April 22, 2025. Each Debenture Unit will have a face value of of CAD 1,120, consisting of CAD 1,000 in principal and CAD 120 in prepaid interest. The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, and such accrued interest will be paid semi-annually, in arrears. At the election of the Company, Prepaid Interest and Accrued Interest may be paid in cash or converted into Shares at a conversion price equal to the maximum Discounted Market Price equal to the maximum Discounted Market Price. The holder may, at its option, convert in full or in part, the Principal at any time prior to the maturity date, being the third anniversary of the issue date, into units of the Company at CAD 0.10 per Unit. Upon conversion of the Principal, Prepaid Interest and unpaid Accrued Interest, will be, at the election of the Company, either paid in cash or converted into Shares at the Interest Conversion Price. Each Unit will consist of one Share and one non-transferable share purchase warrant. Each Unit will consist of one Share and one non-transferable share purchase warrant at an exercise price of CAD 0.15 at any time prior to the Maturity Date. The Company shall have the right to redeem the Convertible Debentures prior to the Maturity Date at any time after 6 months from the issue date, by paying holders in cash the Face Value of the Convertible Debentures, together with all Prepaid and Accrued Interest and a redemption penalty payment of 8% of the Face Value. The closing of the Offering is subject to the receipt of necessary regulatory approvals, including the approval of the TSXV. The Convertible Debentures, Shares, Warrants and any Warrant Shares will be subject to a four month hold period under applicable securities laws and TSXV policies. The Company may pay eligible finders a fee in connection with the Offering.
お知らせ • Apr 22Sirona Biochem Corp. announced that it expects to receive CAD 3 million in funding from Promura GmbHSirona Biochem Corp. announced that it has entered into a investment agreement with Promura GmbH to issue unsecured convertible debentures for gross proceeds of CAD 3,000,000 on April 22, 2025. The debentures will accrue interest at the rate of 12%. The company plans to compensate finders by way of cash fees and warrants. The completion of the private placement is subject to customary conditions, including acceptance from the Toronto stock exchange venture. All securities issued will be subject to a hold period in accordance with TSXV and/or other regulatory requirements.
お知らせ • Apr 05Sirona Biochem Corp. announced that it has received CAD 0.1325 million in fundingOn April 4, 2024, Sirona Biochem Corp closed the transaction. The company has now issued 1,325,000 units at a price of CAD 0.10 per Unit for a gross proceeds of CAD 132,500. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024. No insiders participated in the private placement. No finders' fees were paid from the private placement.
お知らせ • Feb 02Sirona Biochem Corp. announced that it expects to receive CAD 1 million in fundingSirona Biochem Corp. announced that it has entered into a private placement of promissory note for aggregate principal amount of $1,000,000 on January 29, 2024. The transaction will include participation from new lender, 0906462 B.C. Ltd. The promissory note will interest at a rate of 12% per annum. The Company has agreed to, subject to TSX Venture Exchange approval.
お知らせ • Jan 27Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024.
お知らせ • Dec 12Sirona Biochem Corp. Initiates GlycoProteMim™? Trademark for Anti-Aging Molecule TFC-1326Sirona Biochem Corp. announced the trademarking of its anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim. This pivotal decision marks a significant milestone in Sirona Biochem's mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim, filed with the Instituto Nacional da Propriedade Industrial (INPI) and the United States Trademark and Patent Office, demonstrates the company's unwavering commitment to revolutionizing the cosmetics industry with cutting-edge science and unparalleled anti-aging solutions. With over two decades of research and development, Sirona Biochem has developed GlycoProteMim (TFC-1326) into a powerful solution to reverse skin aging. The molecule has proven to be a game-changer in the fight against aging, offering a diverse range of permanent benefits. Sirona Biochem has begun the trademarking process through it's subsidiary TFChem and is actively engaging industry experts to chart the most effective course for commercializing GlycoProteMim™. This strategic move underscores the company's dedication to delivering a unique and transformative anti-aging solution to the $12.5 billion global anti-aging market. The choice to trademark GlycoProteMim goes beyond a mere formality; it stands as a testament to Sirona Biochem's commitment to revolutionizing beauty through scientific innovation. Through rigorous research and clinical trials, the company firmly believes that this name will soon be associated with timeless, radiant skin. Sirona Biochem is certain that GlycoProteMim will surpass the current gold standard, Retinol, in its ability to reverse skin aging. Unlike other products on the market, GlycoProteMim provides powerful results with exceptional tolerability.
お知らせ • Apr 23Sirona Biochem Corp. announced that it expects to receive CAD 0.4 million in fundingSirona Biochem Corp. announced a non-brokered private placement that it will issue up to 400 unsecured convertible debentures units at an issue price of CAD 1,000 per unit for the gross proceeds of up to CAD 400,000 on April 22, 2025. Each Debenture Unit will have a face value of of CAD 1,120, consisting of CAD 1,000 in principal and CAD 120 in prepaid interest. The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, and such accrued interest will be paid semi-annually, in arrears. At the election of the Company, Prepaid Interest and Accrued Interest may be paid in cash or converted into Shares at a conversion price equal to the maximum Discounted Market Price equal to the maximum Discounted Market Price. The holder may, at its option, convert in full or in part, the Principal at any time prior to the maturity date, being the third anniversary of the issue date, into units of the Company at CAD 0.10 per Unit. Upon conversion of the Principal, Prepaid Interest and unpaid Accrued Interest, will be, at the election of the Company, either paid in cash or converted into Shares at the Interest Conversion Price. Each Unit will consist of one Share and one non-transferable share purchase warrant. Each Unit will consist of one Share and one non-transferable share purchase warrant at an exercise price of CAD 0.15 at any time prior to the Maturity Date. The Company shall have the right to redeem the Convertible Debentures prior to the Maturity Date at any time after 6 months from the issue date, by paying holders in cash the Face Value of the Convertible Debentures, together with all Prepaid and Accrued Interest and a redemption penalty payment of 8% of the Face Value. The closing of the Offering is subject to the receipt of necessary regulatory approvals, including the approval of the TSXV. The Convertible Debentures, Shares, Warrants and any Warrant Shares will be subject to a four month hold period under applicable securities laws and TSXV policies. The Company may pay eligible finders a fee in connection with the Offering.
お知らせ • Apr 22Sirona Biochem Corp. announced that it expects to receive CAD 3 million in funding from Promura GmbHSirona Biochem Corp. announced that it has entered into a investment agreement with Promura GmbH to issue unsecured convertible debentures for gross proceeds of CAD 3,000,000 on April 22, 2025. The debentures will accrue interest at the rate of 12%. The company plans to compensate finders by way of cash fees and warrants. The completion of the private placement is subject to customary conditions, including acceptance from the Toronto stock exchange venture. All securities issued will be subject to a hold period in accordance with TSXV and/or other regulatory requirements.
お知らせ • Apr 05Sirona Biochem Corp. announced that it has received CAD 0.1325 million in fundingOn April 4, 2024, Sirona Biochem Corp closed the transaction. The company has now issued 1,325,000 units at a price of CAD 0.10 per Unit for a gross proceeds of CAD 132,500. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024. No insiders participated in the private placement. No finders' fees were paid from the private placement.
お知らせ • Feb 02Sirona Biochem Corp. announced that it expects to receive CAD 1 million in fundingSirona Biochem Corp. announced that it has entered into a private placement of promissory note for aggregate principal amount of $1,000,000 on January 29, 2024. The transaction will include participation from new lender, 0906462 B.C. Ltd. The promissory note will interest at a rate of 12% per annum. The Company has agreed to, subject to TSX Venture Exchange approval.
お知らせ • Jan 27Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024.
お知らせ • Dec 12Sirona Biochem Corp. Initiates GlycoProteMim™? Trademark for Anti-Aging Molecule TFC-1326Sirona Biochem Corp. announced the trademarking of its anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim. This pivotal decision marks a significant milestone in Sirona Biochem's mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim, filed with the Instituto Nacional da Propriedade Industrial (INPI) and the United States Trademark and Patent Office, demonstrates the company's unwavering commitment to revolutionizing the cosmetics industry with cutting-edge science and unparalleled anti-aging solutions. With over two decades of research and development, Sirona Biochem has developed GlycoProteMim (TFC-1326) into a powerful solution to reverse skin aging. The molecule has proven to be a game-changer in the fight against aging, offering a diverse range of permanent benefits. Sirona Biochem has begun the trademarking process through it's subsidiary TFChem and is actively engaging industry experts to chart the most effective course for commercializing GlycoProteMim™. This strategic move underscores the company's dedication to delivering a unique and transformative anti-aging solution to the $12.5 billion global anti-aging market. The choice to trademark GlycoProteMim goes beyond a mere formality; it stands as a testament to Sirona Biochem's commitment to revolutionizing beauty through scientific innovation. Through rigorous research and clinical trials, the company firmly believes that this name will soon be associated with timeless, radiant skin. Sirona Biochem is certain that GlycoProteMim will surpass the current gold standard, Retinol, in its ability to reverse skin aging. Unlike other products on the market, GlycoProteMim provides powerful results with exceptional tolerability.
お知らせ • Jun 29Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing At the ICGEBSirona Biochem Corp. announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology (ICGEB). The compounds, generated by Sirona's subsidiary TFChem, are aimed at expanding Sirona's existing library of antiviral drug candidates. The ICGEB, located in Trieste, Italy, will employ specialized assays developed at their Laboratory of Molecular Virology to screen a library of 18 newly produced candidates, for their potential to inhibit SARS-CoV2. Spearheading the research program is Dr. Alessandro Marcello, a globally recognized authority in Human Virology. Building upon the previous screening results of the initial 20 compounds, these newly selected candidates hold significant promise. Testing is slated to commence within the next month. Sirona Biochem remains committed to advancing the program on antiviral research and remains optimistic about the potential impact these new compound candidates may have in combatting viral diseases.
